°Ê²¼¡¢¤³¤Î¥Ú¡¼¥¸(°Ò³ÊÙÇ×ãÖ÷µÉÚò̺ǹ¥¡©)¤Î¥á¥¤¥ó¥³¥ó¥Æ¥ó¥Ä¤Ç¤¹¡£
Åê¹ÆÆü»þ 2025-8-8 9:48 °Ò³ÊÙÇ×ãÖ÷µÉÚò̺ǹ¥¡© | |
---|---|
¥²¥¹¥È | °Ò³ÊÙÇ¡ÊVigora¡Ë À§°õÅÙÀ½ÅªÕÜ̾ÔãÍÛ黡¤´ÞÍÀ¾ÃÏÆáÈó¡ÊSildenafil Citrate¡Ë¡¤Ö¤±÷ PDE5¡ÊÂè¸Þ·¿&#30967;»ÀÆó&#37231;&#37238;¡ËÍÞÀ©Ñý¡£Â¶ºîÍѵ¡íÛÇ¡²¼¡§áÄÃËÀÀܼõÀ»É·ã»þ¡¤ñó&#20839;îÙÊü°ì&#27687;²½&#27694;¡ÊNO¡Ë¡¤NO Ðò&#21855;ư¡Ö´Ä&#30967;»ÀÄ»¡ÊcGMP¡Ë¡×Ū·ÁÀ®¡¤Æ³Ã×±¢è³·ì´ÉÊ¿³êÈ©Êüò¢¡¤¿Ê¼©Â¥¿Ê·ìή¿ÊÆþ±¢è³³¤ÌÊñ󡤷ÁÀ®ËÖµ¯¡£ PDE5 À§Ê¬²ò cGMP Ū&#37238;¡¤¼© À¾ÃÏÆáÈó²ÄÍÞÀ© PDE5 Ū³èÀ¡¤×ϼ©±äĹ·ì±ÕÄäαºß±¢è³Åª»þ´Ö¡¤²Ã¶¯çбäĹËÖµ¯Úò̡£îÐÕܺ¬Ú¡¡§º¬Ú¡¡ÔThe New England Journal of Medicine¡Õ°ì¹àÎ×¾²¸¦µæ¡ÊGoldstein et al., 1998¡Ë¡¤À¾ÃÏÆáÈó²Äºß12½µ&#20839;²þÁ±Ä¶²á 69% ED´µ¼ÔŪËÖµ¯¸ùǽ¡¤Áê³Ó°Â°ÖÑýŪ21%¡¤¶ñÍðýÃøÎÅÚᣠ44444.png °Ò³ÊÙÇ×ãÖ÷µÉÚò̺ǹ¥¡©»°¸Äïð¸°ÉþÍÑ·úµÄ &#9989; 1. ¶õÊ¢ÉþÍÑ¡¤é»ÚõÛÚÀ¹¹²÷ Õó¶È&#35498;ÌÀ¡§º¬Ú¡é»ÊªÆ°ÎÏÕÜ¡ÊPharmacokinetics¡Ë¸¦µæ¡¤À¾ÃÏÆáÈóºß¶õÊ¢ÉþÍÑ»þ¡¤Â¶·ìÃæÇ»ÅÙ±÷30-60ʬ¾â&#20839;ãÅþºÇ¹âÊö¡ÊTmax¡Ë¡¤Úò̺Dz¡£¼ãçйâ»éËûÁ°ìµ¯¿©ÍÑ¡¤Tmax ²Äǽ±äê2¾®»þ°Ê¾å¡¤¿Ó»ê¸º¼åÚò̡£ &#9989; ·úµÄ¡§ºßÀ°¦Á° ¶õÊ¢ÉþÍѰҳÊÙÇ¡¤°¿»ê¾¯ÈÓ¸åÑÀ¾®»þºÆÉþ黡¤°ÊÄó¾£µÛÚÀΨçÐé»ÚÃɽ¸½¡£ &#9989; 2. À¹Ô°ÙÁ° 30¡Á60 ʬ¾âÉþÍÑ °Ò³ÊÙÇÉÔÀ§ºÅ¾ð黡¤¼©À§é´Í³À¸ÍýÈ¿Øæ&#29986;À¸Úò̡¤¼ûÅëÇÛÀ»É·ãºÍǽËÖµ¯¡£Î×¾²·úµÄºßÀ°¦Á° Ìó30»ê60ʬ¾âÉþÍѰҳÊÙÇ¡¤ìªé»ÚúßÀ¹Ô°Ù³«»Ï»þãÅþºÇ²Â&#29376;ÂÖ¡£îÐÕܺ¬Ú¡¡§¡ÔClinical Therapeutics¡Õ´ü´©»Ø½Ð¡¤À¾ÃÏÆáÈóŪµ¯Úûþ´Ö°Ù30¡Á60ʬ¾â¡¤»ýåô»þ´ÖÌó°Ù4¾®»þ¡ÊEardley et al., 2002¡Ë¡£ &#9989; 3. ÑýÎÌØæ¸Ä¿Í²½¡¤·úµÄ×ÏÄãÑýÎ̳«»Ï »ÔÓ´°Ò³ÊÙǾ︫ÑýḬ̂٠50mg Ï 100mg¡¤½é¼¡»ÈÍѼԷúµÄ×Ï 50mg ³«»Ï¬»îÈ¿Øæ¡¤ºÆ°Í¸Ä¿Íñó½Å¡¢Ç¯óô¡¢·ò¹¯&#29376;¶·Ä´À°¡£¼ãÚòÌÉÔ³î̵ÌÀðýÉûºîÍÑ¡¤ºÍ²Ä¹Íθ¾£»ê100mg¡¨È¿Ç·¼ã½Ð¸½ÉûºîÍÑ¡¤²Ä²þ°ÙȾðù¡Ê25mg¡Ë¡£îÐÕÜ·úµÄ¡§º¬Ú¡¡ÔEuropean Urology¡Õ´ü´©¡¤PDE5 ÍÞÀ©ÑýÑýÎÌØæ°ÍÉ¿Íǯóô¡¢´Î¿Õ¸ùǽçйçÊ»ÍÑ黿ʹԸÄÊ̲½Ä´¡ÊHatzichristou et al., 2010¡Ë¡£ VIGORA_ÉûËÜ.png °Ò³ÊÙÇÉûºîÍÑçÐÍÑé»Ãí°Õ»ö¹à ϶¾ PDE5 ÍÞÀ©Ñý°ìÜ롤°Ò³ÊÙÇÉûºîÍÑ¿°ÙíËÈù³îû»Ã¡¤¾ï¸«Êñ³ç¡§ ƬÄË ¾Ã²½ÉÔŬ ÌÌÉôĬ¹È É¡ºÉ »ëë´ÌϸҡÊÍõ¿§»ëë´¡Ë Âç¿Ú˿ͺßé»Ú÷뫸åÐò¼«Á³¾ÃÂࡣâ¼ã½Ð¸½Óî½Å¾É&#29376;¡ÊÇ¡¡§¶»ÄË¡¢»ëÎÏÁÓ¼º¡¢ËÖµ¯Ä¶²á4¾®»þ¡Ë¡¤ØæÎ©Â¨½¢îС£ &#10071; ÉÔ·úµÄ»ÈÍѰҳÊÙÇŪ²·²¡§ ÀµºßÉþÍÑ ¾Ë»ÀóÅÎàé»Êª¡ÊÇ¡¾Ë»À´ÅÌý¡Ë¼Ô Í Óî½Å¿´·ì´É¼ÀÉ¡¢ÉÔãÓÄê¿´¹ÊÄËÉÂ»Ë¼Ô ²áµî»ÈÍÑÀ¾ÃÏÆáÈóÁ½²áÉÒÈ¿Øæ¼Ô ´Î¿Õ¸ùǽÉÔÁ´¡¢Äã·ìÔÚ¡Ê<90/50 mmHg¡Ë´µ¼Ô ÀÁ±÷»ÈÍÑÁ°çÐîлհ¿é»»ÕƤÏÀ¸Ä¿ÍÉ»˵ÚÉ÷ðªÉ¾ÐÆ¡£ °Ò³ÊÙÇ»ÈÍÑ¿´ÆÀʬµý¡§µÉÕôÊý¼°¡¤¿¿ÅªÍ´¶¡ª µö¿»ÈÍѼԲóñ¿É½¼¨¡¤¶õÊ¢ÉþÍѰҳÊÙÇ¡¢À°¦Á°40ʬ¾â&#20839;ÉþÍÑ¡¢ÅëÇÛŬáľð¶çлɷ㡤ǽÌÀðýÄó¾£¹ÅÅÙçлýµ×ÅÙ¡£Ìéͺ³¿Í½é¼¡ÝóÚò̡¤¸åÐÔ⤸½À§¡ÖÈÓ¸åÇϾåµÉ¡×°¿¡ÖÂÀ¶ÛÄ¥¡×¡¤Æ³Ã×µÛÚÀçп´Íý±Æ¶Á½êÃס£ °øº¡¡¤°Ò³ÊÙÇ×ãÖ÷µÉ¡¤¿¿ÅªÐò·èÄêÚòÌÍÝóÍ´¶¡ª °Ò³ÊÙǹØÇã¿äÁ¦çÐËɵ¶ÄóÀà ÌÜÁ°»ÔÌ̾åÐñé»&#30526;¿¡¤Ìà¶À§°Ê°õÅÙÔãÍÛé»°Ù̾Ū&#29986;ÉÊ¡¤¼ãÐÔ¸»ÉÔÌÀ¡¢ÊñêæÉÔÀ¶Á¿¡¤×̲ÄǽÀ§Îô¼Á&#20223;ËÁÉÊ¡£°ÙλÊݾã°ÂÁ´¡¤·úµÄÁªÚ¤ ¹çˡ黶ɰ¿¿®ì¥Îɹ¥ÅªÀþ¾åÊ¿Âæ¹ØÇã°Ò³ÊÙÇ¡£ÎãÇ¡¡§¡Ú¹¯ÜÛé»¶É¡Ãwww.kl19.tw¡Û°ÙÂæßÔ¸ýÈêÎɹ¥ÅªÃËÀ·ò¹¯ÌÖãëÇ·°ì¡¤Äó¶¡ÀµÉʰõÅÙ°Ò³ÊÙǹØÇã¿äÁ¦¡¤Ê²ĻðëÎÕó¶Èé»»Õ¡£ Èù¿®&#22270;ÊÒ_20250807082448.png åÁ·ë¡§°Ò³ÊÙÇ×ãÖ÷µÉÚò̺ǹ¥¡©»°Í×ÁÇÏ´µ 1. &#9989; ¶õÊ¢ÉþÍÑ¡¤µÛÚÀ²÷® 2. &#9989; À¹Ô°ÙÁ°30¡Á60ʬ¾âÉþÍÑ 3. &#9989; ÑýÎ̸ÄÊ̲½¡¢ÈòÌÈЬµÉЬº® ÂþÍװ;ÈîÐÕÜ·úµÄÀµ³ÎÉþÍѰҳÊÙÇ¡¤½¢Ç½°ÂÁ´ËôÍÚÃÃϲþÁ±ËÖµ¯¸ùǽ¡¤ìªÀÀ¸³èÙ²²ó¼«¿®çзã¾ð¡£ÉÔ²á¼ãÍËýÀɰ¿Ä¹´üÉþ黼ԡ¤µÆÀ°ìÄêÍ×Àè»ðëÎîлպÆÍÑ黡¤ºÍǽ¹ßÄãÉ÷𪡢³ÎÊݰÂÁ´ Áêïð&#29986;ÉÊ¿äÁ¦¡§ùþԢɬˮ&#8194;°õÅÙ¿ÀÌý±ä»þÊ®Ñý¶âºÈÇ ²äÍå»ÛÂÙó¶Åç±Âè»°Âå¾£µéÈÇ&#8194; ū̴ã¹îÍåÇ«üî²ÉÉØ&#8194;É©·ÁÒÖÚðҼ©¹ÝKAMAGRA&#8194;&#8194;ÀµÉʺÔÍø»Î20mg ÈþÔ¢üî¶â ¹¹Â¿&#29986;Éʾܾð¿ÊÆþ¹¯ÜÛé»¶É¡§www.kl19.tw24¾®»þµÒÉþline:kl198888 »ðëÎ ±ä¿&#38321;즡§ÆüËÜÆ£Áǵɴ°²Ä°Ê³åÃã¡©&#21654;&#21857;°øÐò´³¾ñé»ÚÃ&#21966; |
°Ê²¼¡¢¤³¤Î¥µ¥¤¥È(¤ß¤ó¤Ê¤ÎÁ¥¶¶)¤Î¥æ¡¼¥¶ÍÑ¥á¥Ë¥å¡¼¤È¡¢ÅÐÏ¿¤µ¤ì¤¿Á¥¶¶ Çð »ÔÀî ½¬»ÖÌî ȬÀéÂå ¤Î´ë¶È¤ªÅ¹¾ðÊó¤Î¥«¥Æ¥´¥ê°ìÍ÷¤Ç¤¹¡£
¤³¤Î¥Ú¡¼¥¸¤ÎÀèÆ¬¤ØÌá¤ë